Chimeric Toxin Selective Pain Neuron Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management therapies, such as spinal opiates, are limited in their applicability and can have unintended effects due to non-selective uptake mechanisms, leading to enhanced pain or other adverse actions, and there is a need for a more targeted approach to treat chronic pain conditions like musculoskeletal and low back pain.
Innovation Solution
A chimeric toxin is developed by linking a clostridial neurotoxin light chain to a peptide ligand specifically targeting neurons involved in pain processing, without a translocation domain, allowing selective uptake and action on pain-transmitting neurons, thereby regulating pain transmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a chimeric toxin with translocation domain is used to target pain neurons, then selective uptake into pain-processing neurons is improved, but permanent and irreversible neuron loss occurs
Solution Approach 1:
The patent extracts and removes the translocation domain from the complete toxin structure, retaining only the light chain portion that contains the enzymatic activity. This extraction allows the toxin to be taken up selectively into pain-processing neurons via the peptide ligand while eliminating the harmful permanent neuron loss effect, achieving reversible pain relief instead
Solution Approach 2:
The patent changes the structural parameter of the toxin by using only the light chain (50-70 kDa) instead of the complete toxin (100-150 kDa). This parameter change transforms the toxin from causing permanent neuron death to providing reversible pain relief, while maintaining selective uptake into target neurons through the peptide ligand
2Object-generated harmful factors
If spinal opiates are used to treat pain, then pain relief is achieved, but non-selective uptake leads to enhanced pain or adverse actions
Solution Approach 1:
The patent segments the toxin into distinct functional components: a peptide ligand for selective targeting of pain-processing neurons and a light chain for enzymatic activity. This segmentation enables selective action on pain neurons while avoiding non-selective uptake effects of spinal opiates, eliminating adverse actions on non-painful sensations
Solution Approach 2:
The patent introduces a peptide ligand as an intermediary that mediates selective uptake into pain-processing neurons. This intermediary ensures that the toxin acts only on the intended target (pain neurons expressing specific receptors) while avoiding non-selective effects on other neurons, thereby improving reliability and reducing adverse actions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric toxin effectively blocks the release of pain-transmitting neurotransmitters, providing long-lasting and reversible pain relief by selectively targeting and inhibiting pain-processing neurons, reducing pain sensation by up to 50% in treated subjects without causing untoward effects on non-painful sensations.
Implementation Method 1
When their respective agonists occupy them they will internalize the bound agonists into the cell
Implementation Method 2
the activation of the terminal opiate receptors blocks the opening of voltage sensitive calcium channels, this presynaptic effect serves to block transmitter release from only these C fiber terminals
Data Source
AI summary
A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.